Skip to main content

Table 2 Key characteristics of participants at baseline in three trials that contributed individual participant data

From: Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials

Characteristic

Aspirin group

(N = 1188)

Placebo group

(N = 1118)

Age (years)

60.1 (8.9)

60.1 (8.6)

Male sex

455 (38.3)

433 (38.7)

Body mass index (kg/m2)

28.8 (5.7)

29.1 (6.0)

Systolic blood pressure (mmHg)

134.8 (14.4)

134.7 (13.8)

Total cholesterol (mmol/l)*

5.66 (1.20)

5.41 (1.16)

Smoking status

 Other

1015 (85.5)

966 (86.5)

 Current

172 (14.5)

151 (13.5)

History of hypertension

 No

469 (39.5)

453 (40.7)

 Yes

718 (60.5)

661 (59.3)

Baseline treatment for hypertension*

 No

489 (61.4)

455 (61.6)

 Yes

307 (38.6)

284 (38.4)

Family history of MI*

 No

666 (84.0)

623 (84.2)

 Yes

127 (16.0)

117 (15.8)

History of RA

 No

898 (98.4)

842 (97.9)

 Yes

15 (1.6)

18 (2.1)

  1. * Data contributed by two trials; values are mean (SD), median (IQR), or n (%); MI, myocardial infarction; rheumatoid arthritis